Form 4: AtriCure Executive Sells 1,500 Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Justin J. Noznesky, Chief Marketing & Strategy Officer of AtriCure, Inc., sold 1,500 shares of common stock at $24.09 per share on May 1, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On May 1, 2024, Justin J. Noznesky, Chief Marketing & Strategy Officer of AtriCure, Inc., sold 1,500 shares of the company's common stock.
- The sale was executed at a price of $24.09 per share.
- The transaction was conducted under a 10b5-1 trading plan adopted on December 12, 2023.
- Following the transaction, Noznesky directly owns 71,284 shares of AtriCure common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports a stock sale under a pre-arranged plan.
Industry Context
Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on any specific non-public information.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 2023-12-12 | Date of adoption of the 10b5-1 trading plan. |
| 2024-05-01 | Date of the stock sale transaction. |
| 2024-05-03 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.